Dianthus Therapeutics CFO Sells $9.5 Million in Stock

114,367 shares were sold for approximately $9.49 million on March 31, 2026, representing 100% of Savitz's direct common stock and reducing his direct ownership of that class to zero. The report is a factual insider divestiture with potential signaling implications for governance or investor sentiment but is unlikely to have major market impact on its own.

Analysis

114,367 shares were sold for approximately $9.49 million on March 31, 2026, representing 100% of Savitz's direct common stock and reducing his direct ownership of that class to zero. The report is a factual insider divestiture with potential signaling implications for governance or investor sentiment but is unlikely to have major market impact on its own.